Anuh Pharma Q3 FY23 earnings call: Revenue & Margins
Q3 FY23 investor presentation: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Anuh Pharma Ltd Q3 FY23 key numbers
- Revenue
- Operating Revenue for the 3 months ended 31/12/2022: Rs. 138.73 Cr, up 21% QoQ (from Rs. 115.07 Cr in the previous quarter).
As stated in Anuh Pharma Ltd's Q3 FY23 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Anuh Pharma Ltd's Q3 FY23 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Operating Revenue for the 3 months ended 31/12/2022: Rs. 138.73 Cr, up 21% QoQ (from Rs. 115.07 Cr in the previous quarter). EBITDA for Q3 FY23: Rs. 14.54 Cr, down 6% QoQ.
From Anuh Pharma Ltd's Q3 FY23 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Operating Revenue for the 3 months ended 31/12/2022: Rs. 138.73 Cr, up 21% QoQ (from Rs. 115.07 Cr in the previous quarter).
- Operating Revenue for the 9 months ended 31/12/2022: Rs. 370.18 Cr, up 3% YoY (from Rs. 357.68 Cr for same period last year).
- Total revenue for 9M FY23: Rs. 375.25 Cr vs Rs. 361.84 Cr in 9M FY22 (3% growth).
- Export sales in 9M FY23: USD 2.65 Million vs USD 1.67 Million in 9M FY22, indicating strong export growth.
- Future outlook expects revenue growth from new product launches (Vildagaliptin, Sulfadimethoxine, Citicoline sodium) and regulatory filings (CEP for Azithromycin, Gliclazide, Sulfadoxine; WHO prequalification for Isoniazid).
2 more points from Anuh Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
EBITDA for Q3 FY23: Rs. 14.54 Cr, down 6% QoQ
Locked: what Anuh Pharma Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
Capital Expenditure Plans
- A dedicated 10,000 sq. ft. in-house R&D facility is operational with 16 scientists for new product/process development and manufacturing improvements.
- The company aims to launch new products developed by R&D in the next 3 months: Vildagliptin, Sulfadimethoxine, and Citicoline sodium.
- They expect CEP (Certificate of Pharmaceutical Product) for Azithromycin, Gliclazide, and Sulfadoxine within the year; WHO prequalification for Isoniazid is also expected.
- Existing infrastructure includes modern reactors, filtration and drying equipment compliant with cGMP, enabling scaled production from lab to pilot plant levels.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
Page 12 shows a historical Debt to Equity ratio trend for five years, with figures: 0.02, 0.03, 0.27,…
Locked: what Anuh Pharma Ltd said on fundraising
Also locked on this page: margins, order book
Free account, 30 seconds. No card needed.
Order Book & Pipeline
See what Anuh Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Anuh Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- FDC (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anuh Pharma Ltd Q3 FY23 results?
Operating Revenue for the 3 months ended 31/12/2022: Rs. 138.73 Cr, up 21% QoQ (from Rs. 115.07 Cr in the previous quarter). EBITDA for Q3 FY23: Rs. 14.54 Cr, down 6% QoQ.
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
- A dedicated 10,000 sq.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.